{"filings":[{"id":869720,"accession_number":"0001193125-26-257978","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2026-06-04T23:41:10+00:00","items":["5.07"],"status":"ready","headline":"LeMaitre Vascular 2026 annual meeting results; director John Roush gets 29% withheld votes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Two Class II directors elected: David B. Roberts (18.9M for, 1.25M withheld) and John A. Roush (14.2M for, 5.9M withheld).","Advisory vote on executive compensation approved: 19.3M for, 0.8M against, 13.6K abstain.","Ratification of Grant Thornton as auditor for 2026 approved: 21.2M for, 108.5K against.","Total shares present/proxy: 21.3M of 22.8M outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91589,"accession_number":"0001193125-26-206578","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q1 2026 sales $66.6M (+11%), EPS $0.68 (+42%); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $66.6M (up 11% YoY, 10% organic); gross margin 72.7% (+350 bps); EPS $0.68 (+42%).","Operating income $17.8M (+41%), op margin 27%; cash grew to $367.2M.","Artegraft grew 36% worldwide; records for grafts (+20%), valvulotomes (+15%), carotid shunts (+11%).","Quarterly dividend $0.25/share (payable June 4, record May 21); $100M share repurchase program active.","FY 2026 guidance: sales $277-283M (mid $280M, +12%), EPS $2.93-3.08 (mid $3.00, +26% adj.)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":66551000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91588,"accession_number":"0001193125-26-153779","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"LeMaitre Vascular director Bridget Ross not standing for re-election; board rebalanced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bridget Ross will not stand for re-election as Class II director at June 2, 2026 Annual Meeting, serving until term ends; no disagreement with company.","David B. Roberts nominated as Class II director; will resign Class I directorship contingent on election, to rebalance board classes.","Board reduced from eight to seven members effective upon Ms. Ross's departure and Mr. Roberts' class transfer.","Post-meeting board composition: 2 Class I, 2 Class II, 3 Class III directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101792,"accession_number":"0001193125-26-071954","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q4 2025 sales $64.5M (+16%), EPS $0.68 (+39%), raises dividend 25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 sales $64.5M (+16% YoY, +15% organic); diluted EPS $0.68 (+39%).","Gross margin 71.7% (+240 bps); operating income $18.8M (+47%).","Quarterly dividend increased 25% to $0.25/share; payable March 26, 2026 to holders of record March 12, 2026.","Board authorized $100M share repurchase program, expiring February 18, 2027.","FY2026 guidance: sales mid $280M (+12%), adj. op. income +21%, adj. EPS +22%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":249602000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118113,"accession_number":"0001193125-25-270458","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K/A","filed_at":"2025-11-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LeMaitre Vascular Board adopts annual say-on-pay votes after stockholder preference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted at June 2, 2025 annual meeting for annual say-on-pay frequency.","Board determined to hold future advisory say-on-pay votes every year.","No other changes to the original Form 8-K filed June 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118114,"accession_number":"0001193125-25-269454","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q3 sales $61.0M (+11%), EPS $0.75 (+54%); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 sales $61.0M (+11% YoY, +12% organic); Grafts +23%, Shunts +18%, Artegraft +33%.","GAAP diluted EPS $0.75 (+54%); adjusted EPS $0.62 (+27%).","Adjusted gross margin 70.8% (up 300 bps) on pricing and manufacturing efficiencies.","Full-year 2025 guidance raised: sales $247-249M, EPS $2.48-2.53 (midpoint +30%).","Quarterly dividend $0.20/share, payable Dec 4 to holders of record Nov 20."],"consensus_eps_estimate":null,"consensus_eps_actual":1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":185149000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134569,"accession_number":"0001437749-25-024862","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Vascular Q2 sales up 15% to $64.2M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 EPS $0.60 (+16% YoY); sales $64.2M (+15% organic) driven by catheters (+27%) and grafts (+19%).","Gross margin 70.0% (+110 bps); operating income $16.1M (+12%).","Full-year guidance raised: sales $248-$254M (midpoint +14%), EPS $2.23-$2.37 (midpoint +19%).","Quarterly dividend of $0.20/share declared, payable Sept 4, 2025 to holders of record Aug 21.","Cash increased $16.9M sequentially to $319.5M; $75M share repurchase program active through Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":124103000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151425,"accession_number":"0001437749-25-019314","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LeMaitre Vascular holds 2025 annual meeting; all four proposals approved by stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected three Class I directors: LeMaitre (18.4M for, 1.6M withheld), Roberts (18.2M for, 1.8M withheld), Shadan (15.2M for, 4.8M withheld).","Advisory vote on executive compensation passed with 19.1M for, 0.9M against, 36.6K abstain.","Stockholders selected '1 year' frequency for future advisory votes on executive compensation (16.99M for).","Ratified Grant Thornton LLP as independent auditor for 2025 with 21.0M for, 43K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151424,"accession_number":"0001437749-25-014093","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Vascular Q1 sales $59.9M (+12% YoY), raises FY guidance, declares $0.20 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 sales $59.9M, +12% reported (+13% organic); EPS $0.48, +10% YoY.","FY 2025 sales guidance raised to $242-249M (mid $245M, +13% organic) from prior $239M.","Quarterly dividend of $0.20/share declared, payable May 29 to holders of record May 15.","Artegraft received MDR CE Mark on April 29; European launch to begin.","Ended Elutia porcine patch distribution agreement on April 30 (U.S. hospital sales $5.0M in 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":59871000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170304,"accession_number":"0001437749-25-005495","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q4 sales $55.7M (+14%), EPS $0.49 (+30%), raises dividend 25%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $55.7M (+14% organic), EPS $0.49 (+30%), op income $12.9M (+26%).","Quarterly dividend increased 25% to $0.20/share, payable March 27 to March 13 record date.","Board authorized $75M share repurchase program through Feb 2026.","Issued $172.5M 2.50% convertible notes due 2030 in Dec 2024, net proceeds $167.7M.","FY2025 guidance: sales $239.1M mid (+9%, +10% organic), EPS $2.24 mid (+16%)."],"consensus_eps_estimate":null,"consensus_eps_actual":1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":219863000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170303,"accession_number":"0001437749-25-003679","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"LeMaitre Vascular appoints Dorian LeBlanc as CFO; base salary $565,000, target bonus $225,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dorian LeBlanc appointed CFO effective March 10, 2025; previously CFO at LumiraDx (acquired by Roche).","Annual base salary $565,000; target performance bonus $225,000; annual equity award $375,000 (4-year vesting).","One-time RSU grant of $100,000 with 4-year vesting; eligible for 401(k) match, 25 vacation days.","Severance: $100,000 if termination without cause before Mar 10, 2028; after, greater of 2 weeks' salary per year or $225,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187309,"accession_number":"0001104659-24-130155","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"LeMaitre Vascular issues $172.5M of 2.50% convertible notes due 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $150M principal amount plus $22.5M from initial purchasers' option exercise.","Notes bear interest at 2.50% per annum, mature Feb 1, 2030.","Initial conversion price ~$119.73 per share, convertible into common stock at company's election.","Notes unsecured senior obligations; net proceeds for working capital, general purposes, potential acquisitions.","Issued under Rule 144A; shares upon conversion exempt under Section 3(a)(9)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187308,"accession_number":"0001104659-24-129159","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LeMaitre Vascular prices $150M convertible senior notes offering","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$150M aggregate principal of 2.50% Convertible Senior Notes due 2030, interest payable semi-annually.","Initial conversion price ~$119.73/share, ~30% premium over $92.10 closing price on Dec. 16, 2024.","Net proceeds ~$145.9M (or ~$167.8M if initial purchasers fully exercise $22.5M greenshoe).","Proceeds to be used for working capital, general purposes, and potential acquisitions.","Notes are senior unsecured; redeemable by company after Feb. 5, 2028 under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187307,"accession_number":"0001104659-24-128674","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"LeMaitre Vascular announces $150M convertible senior notes offering due 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offering of $150M aggregate principal amount of Convertible Senior Notes due 2030.","Initial purchasers granted option to buy up to an additional $22.5M in notes.","Notes mature Feb 1, 2030, convertible into cash, stock, or combination at company's election.","Proceeds for working capital and general purposes, including potential acquisitions.","Private offering to qualified institutional buyers under Rule 144A; not registered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187306,"accession_number":"0001437749-24-032784","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Vascular Q3 sales up 16% to $54.8M, EPS $0.49 (+46%), raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 sales $54.8M (+16% organic); diluted EPS $0.49, +46% YoY.","Gross margin 67.8% (+280 bps) on price increases and manufacturing efficiencies.","Full-year guidance raised: sales $219-221M, op margin 24%, EPS $1.91-1.96.","Quarterly dividend of $0.16/share declared, payable Dec 5 to holders of record Nov 21.","Cash increased $10.8M sequentially to $123.9M; $50M share repurchase program ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":164146000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203814,"accession_number":"0001437749-24-027754","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Joseph P. Pellegrino Jr. to retire effective March 7, 2025; remains on Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pellegrino will retire as employee and CFO on March 7, 2025, after 2024 10-K filing; stays on Board until June 2027.","Company to conduct search for replacement CFO; Pellegrino to assist in hiring and onboarding.","Reaffirms August 1, 2024 financial guidance for Q3 and full-year 2024.","Pellegrino served 19 years as executive; was re-elected to Board in June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203813,"accession_number":"0001437749-24-024304","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q2 EPS $0.52 +44%, FY guidance raised; dividend $0.16","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $55.8M +11% (+12% organic); EPS $0.52 +44% vs Q2 2023.","Gross margin 68.9% (+490 bps); operating income $14.4M +52%.","Allografts +30%, bovine patches +12%, carotid shunts +22% led growth.","Q3 guidance: sales $52.7-54.7M, EPS $0.42-0.46; FY guidance raised to sales $218.8M, EPS $1.82-1.91.","Quarterly dividend $0.16/share payable Aug 29, record Aug 15."],"consensus_eps_estimate":null,"consensus_eps_actual":0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":109327000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220414,"accession_number":"0001437749-24-019032","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Director Jasinski fails to win majority vote at annual meeting; board rejects resignation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lawrence J. Jasinski received 8.28M for vs 11.31M withheld, triggering resignation policy; board rejected resignation on June 3.","Shareholders approved amendment to stock option plan, authorizing 1,000,000 new shares for issuance.","Advisory vote on executive compensation approved (19.12M for, 0.62M against).","Ratification of Grant Thornton LLP as auditor for 2024 approved (20.64M for, 0.09M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220413,"accession_number":"0001437749-24-014372","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Vascular Q1 sales $53.5M (+14%), EPS $0.44 (+62%); raises FY op. margin guidance to 22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net income $9.9M (+64%); gross margin 68.6% (+300 bps) on price increases and manufacturing efficiencies.","Allografts (+31%), carotid shunts (+27%), and APAC sales (+44%) led growth; organic sales +11%.","Board declared $0.16/share dividend payable May 30 to holders of record May 16.","FY 2024 guided sales $212.7-217.3M (+11%), EPS $1.73-1.84 (+33% vs. FY 2023), operating margin 22%.","Share repurchase program of up to $50M authorized through Feb 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":53478000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240056,"accession_number":"0001437749-24-005732","cik":1158895,"company_name":"LEMAITRE VASCULAR INC","ticker":"LMAT","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"LeMaitre Q4 sales $48.9M (+19%), EPS $0.38 (+49%); declares $0.16 dividend, $50M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 sales $48.9M (+19% YoY), net income $8.5M (+50%), EPS $0.38 (+49%).","Gross margin 68.1% (+450 bps) driven by ASP increases and manufacturing efficiencies.","Segment highlights: allografts +52%, bovine patches +18%, EMEA sales +21%.","Full year 2024 guidance: sales $209.7-$214.3M (midpoint +10%), EPS $1.60-$1.71.","Board declares $0.16/share dividend (payable Mar 28) and authorizes $50M share buyback."],"consensus_eps_estimate":null,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":193484000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2159851833.4141245,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}